Recalls for GBCA

Gadolinium-based Contrast Agents for Magnetic Resonance Imaging (MRI): Drug Safety Communication - FDA Evaluating the Risk of Brain Deposits With Repeated Use
07/27/2015 Medical Recall

Health care professionals should consider limiting GBCA use to clinical circumstances in which the additional information provided by the contrast is necessary.

  • Company: